Regulus Therapeutics Inc.

The Burnham Institute

Pharmakea, Inc.

Deidre A MacKenna

Balkrishen Bhat

Jeremy Duffield

Erkki I Ruoslahti

John Howard Hutchinson

Jillian Frances Evans

Gretchen Bain

Described herein is the use of a LOXL2 inhibitor in the treatment or prevention of conditions, diseases, or disorders associated with LOXL2 activity.

Uses of a lysyl oxidase-like 2 inhibitor

Provided herein are methods for the treatment of Alport Syndrome, using modified oligonucleotides targeted to miR-21. In certain embodiments, a modified oligonucleotide targeted to miR-21 improves kidney function and/or reduces fibrosis in subjects having Alport Syndrome. In certain embodiments, administration of a modified oligonucleotide targeted to miR-21 delays the onset of end-stage renal disease in a subject having Alport Syndrome. In certain embodiments, a modified oligonucleotide targeted to miR-21 delays the need for dialysis or kidney transplant in a subject having Alport Syndrome.

Methods for treatment of alport syndrome

The present invention provides a heart homing peptide that contains the amino acid sequence GGGVFWQ (SEQ ID NO: 2); HGRVRPH (SEQ ID NO: 3); VVLVTSS (SEQ ID NO: 4); CLHRGNSC (SEQ ID NO: 9); or CRSWNKADNRSC (SEQ ID NO: 10) and further provides conjugates in which a heart homing peptide is linked to a moiety such as a therapeutic agent. The conjugates of the invention are useful for treating cardiovascular diseases such as atherosclerosis and restenosis.

Heart homing conjugates

Heart homing peptides and methods of using same

Growing community of inventors

San Diego, CA, United States of America

Deidre A MacKenna